Active Research Studies thenetnow
INFANT VACCINE ~
Actively Seeking healthy infants (42 to 98 days old) to participate in a safety study of a new 20-valent pneumococcal vaccine.
DIABETES & CHRONIC KIDNEY DISEASE ~
Actively seeking individuals, 18 years or older, to participate in a research study to look at how well Semaglutide works when compared to the ‘dummy medicine’ in slowing the growth and worsening of diabetic kidney disease in those with Type 2 Diabetes.
Actively seeking men and women, between 40 and 80 years old, to test the safety and tolerability of study drug in patients with moderate-to-severe COPD with type 2 inflammation.
RSV VACCINE ~
Actively Seeking non-pregnant women, ages 18 – 45 years of age, to help evaluate the safety and immunogenicity of an RSV vaccine.
RSV = Respiratory Syncytial Virus
Atopic Dermatitis ~
Actively Seeking men and woman (ages 2+) with mild-to-moderate atopic dermatitis to evaluate the efficacy and safety of maintenance treatment and flare reduction with Crisaborole Ointment, 2%, once daily over 52 weeks
Diabetes and Cardiovascular Disease ~
Actively seeking men and women (ages 40+) to test the effectiveness of 2 different study drugs on major cardiovascular events in patients who have Type II Diabetes.
URINARY STRESS INCONTINENCE (SUIs)
A new medical treatment for women who are pre-menopausal, 18-50 years of age, who experience stress incontinence.
STATIN INTOLERANCE ~
To assess the effects of Bempedoic Acid on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant.
DIABETES & CVD ~
Observing the effect of study medication on patients with Type II Diabetes and high cardiovascular disease or risks.
Comparing the effectiveness and safety of an investigational once-weekly drug versus Semaglutide as an add-on therapy to metformin in patients with Type II Diabetes.
Diabetes Add-On Therapy ~
An open-label trial comparing efficacy and safety of tirzepatide versus semaglutide
once weekly as add-on therapy to metformin in patients with Type II Diabetes.